Verfahren zur Herstellung von Benzodiazepin-Derivaten

摘要

1,050,401. Benzodiazepinones. F. HOFFMANN-LA ROCHE & CO. A.G. Feb. 17, 1964 [Feb. 19, 1963], No. 6452/64. Heading C2C. Novel compounds of the general formula (wherein R1 represents -C n H 2n -halogen, in which -C n H 2n - is a straight or branched C 2-7 alkylene group interposing at least two carbon atoms between the N and halogen atoms, R2 represents a lower alkyl group, R3 a halogen atom and R4 a halogen atom, CF 3 or NO 2 , and the broken lines denote that the substituents attached thereby are optional), and their acid addition salts, are prepared by converting the corresponding 1-unsubstituted compounds to their alkali metal derivatives and reacting these with dihalo compounds X-C n H 2n -Z (wherein X and Z represent identical or different halogen atoms) and, if desired, converting the products into acid addition salts. The products may be converted into compounds of the general formula (wherein R‹ represents a lower alkyl group, the curved arrow represents the optional presence of a 4,5-double bond when R‹ is absent, R11 represents -C n H 2n -N(RaRb) in which Ra and Rb are lower alkyl groups which may be joined directly or through O or N (the latter optionally carrying a lower alkyl, lower hydroxyalkyl, lower alkoxyalkyl or-in 4,5-unsaturated compounds-a lower alkenyloxyalkyl radical) to form, with the N atom to which they are attached, a 5- or 6-membered heterocyclic ring, and R40 represents a halogen atom, CF 3 or-in 4,5-unsaturated compounds-NO 2 ) by the further step or steps of reaction with a secondary amine HN(Ra)(Rb) and, optionally, catalytic hydrogenation of the 4,5-double bond (when no NO 2 group is present), and alkylation of the reduction product, and/or introduction of one of the specified substituents into a diaza ring forming the -N(Ra)(Rb) substituent, and/or conversion of the products into acid addition or quaternary salts. (The term " lower ' indicates that radicals so qualified contain not more than 7 carbon atoms). Pharmaceutical preparations having anticonvulsant, analgesic, sedative and muscle relaxant activity comprise a compound of the first general formula above or a pharmaceutically acceptable acid addition salt thereof in admixture with a compatible pharmaceutical organic or inorganic solid or liquid carrier suitable for enteral or parenteral administration.